PIPELINE

Obesity & liver diseases

Product Name

Preclinical

Phase 1

Phase 2

Phase 3

Status¹

Preclinical

Phase 1

Phase 2

Phase 3

Pemvidutide
(ALT-801)

Obesity

55%

Status²

MOMENTUM trial: Interim 24-wk weight loss data in Q1 2023

MOMENTUM trial: Top line 48-wk weight loss data in Q4 2023

Pemvidutide
(ALT-801)

NASH

45%

Status²

24-wk NAFLD readout completed Q4 2022

Initiation of Phase 2b NASH trial mid-year 2023

Preclinical

Phase 1

Phase 2

Phase 3

HepTcell^™

Chronic HBV

55%

Status²

Top line data readout H1 2024

¹ Expected Dates